Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
An Open-Label Study Investigating the 5-HT2A Receptor Occupancy of Remlifanserin (ACP-204) With the PET Radioligand [18F]Altanserin in Healthy Male Participants.
Journal: Clinical pharmacology in drug development
Published: April 03, 2026
Population pharmacokinetics of remlifanserin (ACP-204), a serotonin 2A receptor inverse agonist.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: December 19, 2025
Nonclinical Characterization of ACP-204, a Novel Selective 5-HT2A Receptor Inverse Agonist.
Journal: The Journal of pharmacology and experimental therapeutics
Published: December 02, 2025
A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults.
Journal: Advances in therapy
Published: October 01, 2025
Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study.
Journal: Journal of Alzheimer's disease : JAD
Published: June 16, 2025
Recommendations for management and future investigation of psychosis in neurodegenerative disease: Findings from the International Psychogeriatric Association (IPA) working group.
Journal: International psychogeriatrics
Published: May 23, 2025
Brief operationalized psychosocial interventions for agitation and psychosis: Use in clinical trials and clinical care.
Journal: International psychogeriatrics
Published: May 04, 2025
Natural history and clinical outcomes in patients with Alzheimer's disease-related psychosis by antipsychotic treatment status in the United States.
Journal: Journal of Alzheimer's disease : JAD
Published: November 28, 2024
Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study.
Journal: Journal of Alzheimer's disease : JAD
Published: March 01, 2024
Challenges and proposed solutions to conducting Alzheimer's disease psychosis trials.
Journal: Frontiers in psychiatry
Published: February 08, 2024
Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial.
Journal: Parkinsonism & related disorders
Published: July 14, 2023
Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3).
Journal: Neuropsychiatric disease and treatment
Published: May 02, 2019
Last Updated: 09/26/2026